ALSFRS and Appel ALS scores: Discordance with disease progression

Andrei Voustianiouk, Gregory Seidel, Janki Panchal, Mark Sivak, Adam Czaplinski, Albert Yen, Stanley H. Appel, Dale J. Lange

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Progression of disease and effectiveness of therapy in patients with amyotrophic lateral sclerosis (ALS) are determined by both questionnaire- and examination-based measures. To determine whether both types of measurement tools are equally predictive at all stages of disease, we compared questionnaire-based ALS Functional Rating Scale (ALSFRS) scores to the examination-based Appel ALS (AALS) scores at different stages of disease. Same-day scores were obtained during 174 visits in 62 patients with definite or probable ALS. Using normalized scores, correlation between the scales and predictability were best in mildly affected patients. Predictions of ALSFRS based on AALS scores were less than half as precise in the later stages of disease. Both scales showed significant change with disease progression, but ALSFRS consistently underestimated disease severity defined by AALS (P < 0.001). Questionnaire-based measurements should be compared against objective scales at all stages of disease severity before they are accepted as primary endpoint measures.

Original languageEnglish (US)
Pages (from-to)668-672
Number of pages5
JournalMuscle and Nerve
Volume37
Issue number5
DOIs
StatePublished - May 2008

Keywords

  • ALS
  • ALS clinical trials
  • ALS natural history
  • ALSFRS
  • Amyotrophic lateral sclerosis
  • Appel ALS score

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'ALSFRS and Appel ALS scores: Discordance with disease progression'. Together they form a unique fingerprint.

Cite this